Abeona Therapeutics Inc. (ABEO) earnings

ABEO earnings moved a median of +5.55% by the close. Quarterly and annual ABEO reports and results, each read against the price at its own news timestamp. Back to the ABEO overview →

22 measured ABEO earnings events.

Where these ABEO earnings landedvs 22 measured ABEO earnings reactions
ABEO earningsMiddle 50% · -1.40% to +8.33%Zero: 0.00%Median: +5.55%Median +5.55%-15.00%0+15.00%
Middle 50% of ABEO earnings reactions-1.40% to +8.33%
Median reaction (to close)+5.55%
Measured reactions22
Point-in-time · zero look-ahead

Half of the 22 ABEO earnings events with a measured close landed between -1.40% and +8.33%; 68% closed up.

DateHeadlineEvent5-minTo close
Abeona Therapeutics® Reports Second Quarter 2026 Results and Provides Business UpdatePress release+5.91%+4.19%
Form 10-Q ABEONA THERAPEUTICS INC. For: Jun 30SEC filing · Form 10-Q+5.91%+4.19%
Abeona Therapeutics® to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026Press release+2.06%+1.77%
Abeona Therapeutics® Reports First Quarter 2026 Results and Provides Pipeline UpdatePress release-1.29%-1.72%
Form 10-Q ABEONA THERAPEUTICS INC. For: Mar 31SEC filing · Form 10-Q-1.29%-1.72%
Form 10-K ABEONA THERAPEUTICS INC. For: Dec 31SEC filing · Form 10-K-4.39%-0.42%
Abeona Therapeutics® Reports Third Quarter 2025 Financial Results and Corporate UpdatesPress release+10.00%+7.39%
Form 10-Q ABEONA THERAPEUTICS INC. For: Sep 30SEC filing · Form 10-Q+10.00%+7.39%
Abeona Therapeutics® Reports Second Quarter 2025 Financial Results and Corporate UpdatesPress release+0.58%+5.55%
Form 10-Q ABEONA THERAPEUTICS INC. For: Jun 30SEC filing · Form 10-Q+0.58%+5.55%
Abeona Therapeutics® Reports First Quarter 2025 Financial Results and Corporate UpdatesPress release+1.49%+8.02%
Form 10-Q ABEONA THERAPEUTICS INC. For: Mar 31SEC filing · Form 10-Q+1.49%+8.02%
Form 10-K ABEONA THERAPEUTICS INC. For: Dec 31SEC filing · Form 10-K-0.84%-4.10%
Abeona Therapeutics® Reports Third Quarter 2024 Financial Results and Recent Corporate UpdatesPress release-5.08%-5.56%
Form 10-Q ABEONA THERAPEUTICS INC. For: Sep 30SEC filing · Form 10-Q-5.08%-5.56%
Abeona Therapeutics® Reports Second Quarter 2024 Financial Results and Concludes Type A Meeting with FDA to Align on Upcoming Pz-cel BLA ResubmissionPress release+0.00%+10.00%
Form 10-Q ABEONA THERAPEUTICS INC. For: Jun 30SEC filing · Form 10-Q+0.00%+10.00%
Abeona Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate ProgressPress release+5.66%+11.09%
Form 10-Q ABEONA THERAPEUTICS INC. For: Mar 31SEC filing · Form 10-Q+5.66%+11.09%
Form 10-K ABEONA THERAPEUTICS INC. For: Dec 31SEC filing · Form 10-K-9.39%-11.07%
Abeona Therapeutics Reports Third Quarter 2023 Financial Results and Corporate DevelopmentsPress release-2.22%+8.43%
Form 10-Q ABEONA THERAPEUTICS INC. For: Sep 30SEC filing · Form 10-Q-2.22%+8.43%
That’s how ABEO usually reacts to earnings — get an email when it moves on news →
Keep exploring

More ABEO: analyst actions · SEC filings · ABEO overview →

Other Healthcare names and their earnings

TickerEventsMedian 30-min% positive
Veracyte, Inc. (VCYT)414-0.24%42%
Verastem, Inc. (VSTM)414-0.11%48%
Align Technology, Inc. (ALGN)411-0.02%48%
EyePoint, Inc. (EYPT)409-0.24%46%

Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.